scholarly journals Liver transplantation in pediatric patients with progressive familial intrahepatic cholestasis: Single center experience of seven cases

Author(s):  
Jung-Man Namgoong ◽  
Shin Hwang ◽  
Hyunhee Kwon ◽  
Suhyeon Ha ◽  
Kyung Mo Kim ◽  
...  
Author(s):  
Fatma İlknur Varol ◽  
Mukadder Ayşe Selimoğlu ◽  
Şükrü Güngör ◽  
Sezai Yılmaz ◽  
İbrahim Tekedereli

2013 ◽  
Vol 17 (2) ◽  
pp. 158-167 ◽  
Author(s):  
Irene K. Kim ◽  
Anna-Kaisa Niemi ◽  
Casey Krueger ◽  
Clark A. Bonham ◽  
Waldo Concepcion ◽  
...  

2007 ◽  
Vol 11 (2) ◽  
pp. 152-159 ◽  
Author(s):  
Ilknur Erol ◽  
Füsun Alehan ◽  
Figen Ozcay ◽  
Oguz Canan ◽  
Mehmet Haberal

Medicina ◽  
2021 ◽  
Vol 57 (8) ◽  
pp. 854
Author(s):  
Safak Gül-Klein ◽  
Robert Öllinger ◽  
Moritz Schmelzle ◽  
Johann Pratschke ◽  
Wenzel Schöning

Background and Objectives: Progressive familial intrahepatic cholestasis (PFIC) is a rare autosomal recessive inherited disease divided into five types (PFIC 1-5). Characteristic of all types is early disease onset, which may result clinically in portal hypertension, fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic manifestations. Liver transplantation (LT) is the only successful treatment approach. Our aim is to present the good long-term outcomes after liver transplantation for PFIC1, focusing on liver function as well as the occurrence of extrahepatic manifestation after liver transplantation. Materials and Methods: A total of seven pediatric patients with PFIC1 underwent liver transplantation between January 1999 and September 2019 at the Department of Surgery, Charité Campus Virchow Klinikum and Charité Campus Mitte of Charité-Universitätsmedizin Berlin. Long-term follow-up data were collected on all patients, specifically considering liver function and extrahepatic manifestations. Results: Seven (3.2%) recipients were found from a cohort of 219 pediatric patients. Two of the seven patients had multilocular HCC in cirrhosis. Disease recurrence or graft loss did not occur in any patient. Two patients (male, siblings) had persistently elevated liver parameters but showed excellent liver function. Patient and graft survival during long-term follow-up was 100%, and no severe extrahepatic manifestations requiring hospitalization or surgery occurred. We noted a low complication rate during long-term follow-up and excellent patient outcome. Conclusions: PFIC1 long-term follow-up after LT shows promising results for this rare disease. In particular, the clinical relevance of extrahepatic manifestations seems acceptable, and graft function seems to be barely affected. Further multicenter studies are needed to analyze the clinically inhomogeneous presentation and to better understand the courses after LT.


2004 ◽  
Vol 42 (05) ◽  
Author(s):  
V Stadlbauer ◽  
S Schaffellner ◽  
D Kniepeiss ◽  
E Jakoby ◽  
F Iberer ◽  
...  

Author(s):  
Noor N. Junejo ◽  
Santiago Vallasciani ◽  
Ahmad Alshammari ◽  
Hossam Aljallad ◽  
Saeed Alshahrani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document